Your browser doesn't support javascript.
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.
Zeidan, Amer M; Boddu, Prajwal C; Patnaik, Mrinal M; Bewersdorf, Jan Philipp; Stahl, Maximilian; Rampal, Raajit K; Shallis, Rory; Steensma, David P; Savona, Michael R; Sekeres, Mikkael A; Roboz, Gail J; DeAngelo, Daniel J; Schuh, Andre C; Padron, Eric; Zeidner, Joshua F; Walter, Roland B; Onida, Francesco; Fathi, Amir; DeZern, Amy; Hobbs, Gabriela; Stein, Eytan M; Vyas, Paresh; Wei, Andrew H; Bowen, David T; Montesinos, Pau; Griffiths, Elizabeth A; Verma, Amit K; Keyzner, Alla; Bar-Natan, Michal; Navada, Shyamala C; Kremyanskaya, Marina; Goldberg, Aaron D; Al-Kali, Aref; Heaney, Mark L; Nazha, Aziz; Salman, Huda; Luger, Selina; Pratz, Keith W; Konig, Heiko; Komrokji, Rami; Deininger, Michael; Cirici, Blanca Xicoy; Bhatt, Vijaya Raj; Silverman, Lewis R; Erba, Harry P; Fenaux, Pierre; Platzbecker, Uwe; Santini, Valeria; Wang, Eunice S; Tallman, Martin S.
  • Zeidan AM; Section of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA; Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA. Electronic address: amer.zeidan@yale.edu.
  • Boddu PC; Section of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA; Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.
  • Patnaik MM; Department of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Bewersdorf JP; Section of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA; Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.
  • Stahl M; Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Rampal RK; Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Shallis R; Section of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA; Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.
  • Steensma DP; Department of Hematology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Savona MR; Department of Hematology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
  • Sekeres MA; Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
  • Roboz GJ; Department of Hematology and Oncology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.
  • DeAngelo DJ; Department of Hematology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Schuh AC; Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
  • Padron E; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
  • Zeidner JF; Division of Hematology and Oncology, Lineberger Comprehensive Care Center, University of North Carolina, Chapel Hill, NC, USA.
  • Walter RB; Division of Hematology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Onida F; Department of Hematology, IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
  • Fathi A; Department of Hematology, Centre for Leukemia, Massachusetts General Hospital, Boston, MA, USA.
  • DeZern A; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Hobbs G; Department of Hematology, Centre for Leukemia, Massachusetts General Hospital, Boston, MA, USA.
  • Stein EM; Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Vyas P; MRC Molecular Haematology Unit, BRC Oxford Department of Haematology, University of Oxford, Oxford, UK.
  • Wei AH; Department of Clinical Haematology, Alfred Hospital, Melbourne, VIC, Australia.
  • Bowen DT; Department of Haematology, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK.
  • Montesinos P; Department of Haematology, Hospital Universitario y Politecnico La Fe, Valencia, Spain; CIBERONC, Instituto Carlos III, University of Valencia, Madrid, Spain.
  • Griffiths EA; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Verma AK; Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.
  • Keyzner A; Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Bar-Natan M; Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Navada SC; Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Kremyanskaya M; Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Goldberg AD; Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Al-Kali A; Department of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Heaney ML; Department of Hematology, Herbert Irving Comprehensive Care Centre, Columbia University, New York, NY, USA.
  • Nazha A; Department of Hematology, Cleveland Clinic-Taussig Cancer Institute, Cleveland, OH, USA.
  • Salman H; Department of Internal Medicine, Stony Brook University Cancer Center, Stony Brook, NY, USA.
  • Luger S; Department of Medicine, Hematology and Oncology Division, University of Pennsylvania, Philadelphia, PA, USA.
  • Pratz KW; Department of Medicine, Hematology and Oncology Division, University of Pennsylvania, Philadelphia, PA, USA.
  • Konig H; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, Indiana University, Indianapolis, IN, USA.
  • Komrokji R; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
  • Deininger M; Huntsman Cancer Institute, Department of Medicine, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA.
  • Cirici BX; Clinical Haematology Department, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Bhatt VR; Fred and Pamela Buffett Cancer Center, Department of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Silverman LR; Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Erba HP; Duke Cancer Institute, Department of Medicine, Division of Hematologic Malignancies and Cellular Therapies, Durham, NC, USA.
  • Fenaux P; Department of Hematology, Hôpital St Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; Department of Haematology, Paris University, Paris, France.
  • Platzbecker U; Department of Medicine, Division of Translational Hematology, Leipzig University Hospital, Leipzig, Germany.
  • Santini V; Department of Medicine, University of Florence Medical School, Florence, Italy.
  • Wang ES; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Tallman MS; Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lancet Haematol ; 7(8): e601-e612, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-609322
ABSTRACT
The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Leukemia / Infection Control / Practice Guidelines as Topic / Coronavirus Infections / Betacoronavirus / Myeloproliferative Disorders Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Adult / Humans Language: English Journal: Lancet Haematol Year: 2020 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Leukemia / Infection Control / Practice Guidelines as Topic / Coronavirus Infections / Betacoronavirus / Myeloproliferative Disorders Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Adult / Humans Language: English Journal: Lancet Haematol Year: 2020 Document Type: Article